Brown Advisory Inc. Sells 3,372 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Brown Advisory Inc. decreased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 1.2% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 273,901 shares of the biopharmaceutical company's stock after selling 3,372 shares during the quarter. Brown Advisory Inc.'s holdings in Gilead Sciences were worth $30,691,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Bridgewater Associates LP grew its stake in Gilead Sciences by 122.7% in the 4th quarter. Bridgewater Associates LP now owns 460,936 shares of the biopharmaceutical company's stock valued at $42,577,000 after purchasing an additional 253,994 shares during the period. Nissay Asset Management Corp Japan ADV raised its holdings in shares of Gilead Sciences by 5.2% in the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 284,243 shares of the biopharmaceutical company's stock valued at $26,750,000 after acquiring an additional 14,009 shares in the last quarter. Golden State Wealth Management LLC raised its holdings in shares of Gilead Sciences by 14.5% in the 1st quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company's stock valued at $97,000 after acquiring an additional 109 shares in the last quarter. Ontario Teachers Pension Plan Board raised its holdings in shares of Gilead Sciences by 54.6% in the 4th quarter. Ontario Teachers Pension Plan Board now owns 37,051 shares of the biopharmaceutical company's stock valued at $3,422,000 after acquiring an additional 13,086 shares in the last quarter. Finally, Mufg Securities Americas Inc. purchased a new stake in shares of Gilead Sciences in the 4th quarter valued at about $1,699,000. Institutional investors own 83.67% of the company's stock.

Gilead Sciences Stock Down 4.0%

Shares of Gilead Sciences stock traded down $4.59 on Friday, reaching $109.95. The company's stock had a trading volume of 3,052,960 shares, compared to its average volume of 7,688,323. The firm's fifty day simple moving average is $107.62 and its two-hundred day simple moving average is $104.50. Gilead Sciences, Inc. has a 52 week low of $68.14 and a 52 week high of $119.96. The company has a quick ratio of 1.23, a current ratio of 1.37 and a debt-to-equity ratio of 1.16. The company has a market capitalization of $136.77 billion, a price-to-earnings ratio of 23.15, a P/E/G ratio of 0.73 and a beta of 0.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.04. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The firm had revenue of $6.67 billion for the quarter, compared to analysts' expectations of $6.77 billion. During the same quarter in the prior year, the business earned ($1.32) EPS. The business's quarterly revenue was down .3% on a year-over-year basis. Equities analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Friday, June 13th were issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a yield of 2.87%. The ex-dividend date was Friday, June 13th. Gilead Sciences's dividend payout ratio (DPR) is currently 66.53%.

Analysts Set New Price Targets

Several analysts have weighed in on the company. JPMorgan Chase & Co. raised their price target on Gilead Sciences from $120.00 to $130.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Cantor Fitzgerald started coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $125.00 price target on the stock. Morgan Stanley raised their price target on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a research report on Friday, April 25th. Oppenheimer dropped their price objective on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a report on Friday, April 25th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Gilead Sciences in a report on Wednesday, May 21st. Nine analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, Gilead Sciences has a consensus rating of "Moderate Buy" and a consensus target price of $111.38.

Insider Buying and Selling at Gilead Sciences

In related news, insider Johanna Mercier sold 3,000 shares of the firm's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $110.17, for a total value of $330,510.00. Following the completion of the transaction, the insider directly owned 120,168 shares of the company's stock, valued at approximately $13,238,908.56. This trade represents a 2.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Daniel Patrick O'day sold 10,000 shares of the firm's stock in a transaction on Monday, June 30th. The shares were sold at an average price of $110.45, for a total transaction of $1,104,500.00. Following the completion of the transaction, the chief executive officer directly owned 615,725 shares of the company's stock, valued at approximately $68,006,826.25. This trade represents a 1.60% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 58,500 shares of company stock valued at $6,340,745 in the last three months. 0.27% of the stock is currently owned by corporate insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.